Disclaimer: This content is for informational and educational purposes only and should not be construed as financial or investment advice. Always do your own research and consult a licensed financial advisor before making investment decisions.

Disclosure: The author holds a long position in BFLY.

← Back to Free Index

BFLY

Analysis as of: 2026-03-14

Butterfly Network, Inc.

Butterfly sells the iQ3 handheld ultrasound probe plus workflow software, education, and embedded licensing tools to clinicians, health systems, schools, and partners.

ai hardware healthcare medical devices software

On Yahoo Finance ...

Jump to: Summary • Analysis • Opportunity • Risk • Trends • LE Structure • Third Party Analyst Consensus

Summary

From probe vendor to imaging control layer

The core business now looks credible enough to fund a real option on software, governance, and embedded licensing. Upside is meaningful if enterprise workflow and partner revenue become repeatable before larger OEMs bundle the market away.

Analysis

Thesis

Butterfly can compound if it turns handheld ultrasound from a device sale into a low-cost wedge for enterprise workflow, trust, and embedded licensing; the non-linear upside comes from software, governance, and partner royalties, not just more probes.

Last Economy Alignment

Cheaper cognition should expand ultrasound use and training, while Butterfly still controls the probe and parts of workflow. The score is capped because incumbents can bundle hardware and software, and Butterfly has only moderate lock-in today.

Upgrade to Allocator to also access: Thesis Critique

Opportunity Outlook

Average Implied 5-Year Multiple

3.2x (from 5 most recent analyses)

Reasoning

This is a rerating case only if Butterfly proves it is becoming the operating layer for ultrasound programs, not just a probe seller. A bigger software, trust, and licensing mix can support a healthier multiple even without mega-cap scale, but the rerating depends on repeatable enterprise and partner revenue rather than one-off milestones.

Upgrade to Allocator to also access: Simplified Opportunity Explanation

Risk Assessment

Overall Risk Summary

The main failure mode is not physics; it is adoption bottlenecks in hospital IT, compliance, and partner timelines. If Embedded stays milestone-heavy, HomeCare slips, or TSMC and Cardinal dependencies bite while OEMs bundle handheld ultrasound, Butterfly may not earn the platform multiple in this thesis.

Upgrade to Allocator to also access: Tech Maturity Risk Score, Adoption Timing Risk Score, Moat Strength Risk Score, Capital Needs Risk Score, Regulatory Risk Score, Execution Risk Score, Concentration Risk Score, Unit Economics Risk Score, Valuation Risk Score, Macro Sensitivity Risk Score

Trends

Key Changes

No material de-risking disclosure appeared after the March 3, 2026 conference appearance; the thesis still rests on the February 26, 2026 beat, 2026 guide, and catalyst roadmap.
The clock tightened on two near-term proof points: Beam Steering API in H1 2026 and the first HomeCare commercial agreement by mid-2026.
No new financing or liquidity warning emerged in the last 7-10 days, which leaves the improved 2025 cash profile intact.

Upgrade to Builder to also access: Future Considerations

Last Economy Structure

AI Industrial Score

0.42

They control a real piece of imaging hardware and some of the software hospitals use to manage who scans, where images go, and whether programs stay compliant. AI should make ultrasound easier to use, but bigger device vendors can still squeeze them unless that workflow and partner layer becomes hard to replace.

Upgrade to Reader to also access: Score Decomposition, Confidence Level

Upgrade to Allocator to also access: Obsolescence Vectors, Pricing Fragility

Upgrade to Reader to also access: Constraint Benefit Score, Obsolescence Risk Score

Third Party Analyst Consensus

12-Month Price Target

$5.56

Upgrade to Reader to also access: Bull Case, Base Case, Bear Case

Next Arc Research